| Zeng, Hao |
STROKER, NCT06726421: Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer ( Study) |
|
|
| Recruiting | 3 | 252 | RoW | Stereotactic body radiotherapy (SBRT), Stereotactic ablative radiotherapy, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, Standard systemic therapy | Sun Yat-sen University | Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic | 09/30 | 09/33 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04736108: Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate |
|
|
| Not yet recruiting | 2 | 50 | RoW | Abiraterone acetate, Prednisolone, Goserelin | West China Hospital | Prostate Cancer | 10/22 | 12/24 | | |
NCT05156450: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone | West China Hospital | Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination | 10/23 | 01/24 | | |
SAFH, NCT04387500: Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 41 | RoW | Sintilimab injection plus Inlyta treatment | West China Hospital | Carcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy | 03/25 | 01/26 | | |
NCT06523049: Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy |
|
|
| Not yet recruiting | 2 | 67 | RoW | Vorolanib Tablets, Vorolanib, Sintilimab Injection, Sintilimab | Hao Zeng | Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/26 | 09/26 | | |
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 246 | RoW | Axitinib plus Toripalimab, nephrectomy | ZHOU FANGJIAN, Pfizer | Renal Cell Carcinoma, Neoadjuvant | 07/25 | 03/26 | | |
NCT05996952: RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 77 | RoW | RC48-ADC | West China Hospital, RemeGen Co., Ltd. | Non-muscle Invasive Bladder Cancer | 08/25 | 08/26 | | |
NCT05808608: A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma |
|
|
| Recruiting | 1/2 | 33 | RoW | AK104, Axitinib | Hao Zeng | Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | 10/25 | 12/25 | | |
NCT04660617: A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA) |
|
|
| Not yet recruiting | N/A | 100 | NA | | West China Hospital | Prostate Cancer Metastatic | 11/22 | 04/23 | | |
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study |
|
|
| Recruiting | N/A | 2500 | RoW | | AstraZeneca | NASH With Fibrosis | 12/26 | 12/26 | | |
| Guo, Yingqiang |
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study) |
|
|
| Active, not recruiting | N/A | 88 | RoW | WeFlow-Arch Modeler Embedded Branch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Aortic Arch Aneurysm | 02/25 | 02/29 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
NCT04765605: Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study) |
|
|
| Active, not recruiting | N/A | 120 | RoW | WeFlow-Tbranch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Type B Aortic Dissection | 12/26 | 12/26 | | |
TRAVEL, NCT04436653: THE TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve |
|
|
| Recruiting | N/A | 150 | RoW | Tricuspid Valve Replacement System | Changhai Hospital, Fu Wai Hospital, Beijing, China, Beijing Anzhen Hospital, Wuhan Union Hospital, China, West China Hospital, Xijing Hospital, Guangdong Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | Tricuspid Valve Insufficiency | 06/26 | 06/26 | | |
NCT05194423: THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein |
|
|
| Recruiting | N/A | 150 | RoW | Tricuspid Valve Replacement System via jugular vein | Changhai Hospital, Shanghai Zhongshan Hospital, Fu Wai Hospital, Beijing, China, Beijing Anzhen Hospital, Wuhan Union Hospital, China, West China Hospital, Xijing Hospital, Guangdong Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | Tricuspid Valve Regurgitation | 03/27 | 03/27 | | |
